These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 2233608

  • 21. Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation.
    Breccia M, Mancini M, Nanni M, D'Elia GM, Carmosino I, Latagliata R, Sarlo C, Mandelli F, Alimena G.
    Leuk Res; 2005 Jan; 29(1):33-9. PubMed ID: 15541472
    [Abstract] [Full Text] [Related]

  • 22. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
    Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B, Giagounidis A, Aul C, Gattermann N, Haas R.
    Haematologica; 2006 Dec; 91(12):1596-604. PubMed ID: 17145595
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Hypoplastic myelodysplastic syndrome progressing to acute myelocytic leukemia (M2) after treatment with G-CSF and immunosuppressants].
    Miyata A, Deguchi S, Kikuchi T, Osada T, Sanada H.
    Rinsho Ketsueki; 1998 Jun; 39(6):453-9. PubMed ID: 9695675
    [Abstract] [Full Text] [Related]

  • 28. Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders.
    Occhipinti E, Correa H, Yu L, Craver R.
    Pediatr Blood Cancer; 2005 Mar; 44(3):240-4. PubMed ID: 15368549
    [Abstract] [Full Text] [Related]

  • 29. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
    Shi J, Shao Z, Liu H, Li K, Song L, Zhang Y, Zheng Y, Chen G, Chu Y, He H, Zhao M, He G, Feng B, Hao Y, Yang T, Yang C.
    Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group.
    Barnard DR, Alonzo TA, Gerbing RB, Lange B, Woods WG, Children's Oncology Group.
    Pediatr Blood Cancer; 2007 Jul; 49(1):17-22. PubMed ID: 16856158
    [Abstract] [Full Text] [Related]

  • 34. Telomerase activity in myelodysplastic syndromes.
    Gürkan E, Tanriverdi K, Başlamişli F.
    Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
    Estey EH, Keating MJ, Dixon DO, Trujillo JM, McCredie KB, Freireich EJ.
    Hematol Pathol; 1987 Oct; 1(4):203-8. PubMed ID: 3504436
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.